LYEL
BEARISH
$24.8
Live
Lyell Immunopharma, Inc. · NASDAQ
Target $34.8
(+40.3%)
$7.65
52W Range
$45.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$578.54M
P/E
N/A
ROE
-87.0%
Profit margin
N/A
Debt/Equity
0.21
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
LYEL exhibits critical financial weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe deterioration in fundamental health. Despite a speculative 1-year price rally of 178.7%, the company suffers from extreme operating losses (-1,024,633% margin) and negative revenue growth (-45.50%). The valuation is disconnected from fundamentals, evidenced by an astronomical Price/Sales ratio, while insider sentiment remains bearish with consistent selling by top executives.
Key Strengths
Strong short-term liquidity with a Current Ratio of 5.28
Low leverage with a Debt/Equity ratio of 0.21
Positive analyst sentiment with a mean target price of $34.80
Significant 1-year price momentum (+178.7%)
High gross margin (100%) suggesting a low cost of goods sold for its current stage
Key Risks
Critical financial health as indicated by a 1/9 Piotroski F-Score
Extreme cash burn and negative operating margins
Negative revenue growth (-45.50% YoY) and EPS contraction
Bearish insider activity with 12 sell transactions and 0 buys
Extreme valuation disconnect (P/S ratio of 16,070.67)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
14
Weak
5
30
20
15
0
AI Verdict
High-Risk Speculative
Key drivers: Piotroski F-Score of 1/9, Negative Revenue Growth, Extreme Operating Losses, Bearish Insider Sentiment
Confidence
90%
Value
5/100
Stock trades at a massive premium to revenue and earnings, relying entirely on future clinical success.
Positives
No standout positives identified.
Watchpoints
- P/S ratio is non-functional at 16,070.67
- No Graham Number available due to lack of earnings
Future
30/100
Growth metrics are currently trending downward, contradicting the 'buy' recommendation.
Positives
- Analyst target price suggests 40% upside
Watchpoints
- Revenue growth is declining (-45.50%)
- EPS growth is severely negative (-123.3% YoY)
Past
20/100
Long-term value destruction despite recent short-term volatility.
Positives
- Strong 1-year recovery
Watchpoints
- 5-year return of -92.7%
- Consistent history of earnings misses
Health
15/100
Liquidity is currently sufficient, but the operational health is failing.
Positives
- High Current Ratio (5.28)
- Low Debt/Equity (0.21)
Watchpoints
- Piotroski F-Score 1/9 indicates critical weakness
- ROE of -86.98%
Dividend
0/100
Typical for early-stage biotech.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$24.8
Analyst Target
$34.8
Upside/Downside
+40.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LYEL and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LYEL
Lyell Immunopharma, Inc.
Primary
|
-92.7% | -47.5% | +178.7% | +47.4% | +16.7% | +14.3% |
|
MDXG
MiMedx Group, Inc.
Peer
|
-67.5% | +18.4% | -42.1% | -39.8% | -10.5% | +1.0% |
|
HSTM
HealthStream, Inc.
Peer
|
-8.4% | -25.8% | -36.2% | -22.1% | -3.1% | -2.8% |
|
IRWD
Ironwood Pharmaceuticals, Inc.
Peer
|
-64.3% | -66.3% | +259.4% | +128.3% | -1.4% | +2.5% |
|
BVS
Bioventus Inc.
Peer
|
-36.8% | +662.1% | +6.9% | +32.9% | +2.7% | -3.2% |
LYE
Lyell Immunopharma, Inc.
Primary
5Y
-92.7%
3Y
-47.5%
1Y
+178.7%
6M
+47.4%
1M
+16.7%
1W
+14.3%
MDX
MiMedx Group, Inc.
Peer
5Y
-67.5%
3Y
+18.4%
1Y
-42.1%
6M
-39.8%
1M
-10.5%
1W
+1.0%
HST
HealthStream, Inc.
Peer
5Y
-8.4%
3Y
-25.8%
1Y
-36.2%
6M
-22.1%
1M
-3.1%
1W
-2.8%
IRW
Ironwood Pharmaceuticals, Inc.
Peer
5Y
-64.3%
3Y
-66.3%
1Y
+259.4%
6M
+128.3%
1M
-1.4%
1W
+2.5%
BVS
Bioventus Inc.
Peer
5Y
-36.8%
3Y
+662.1%
1Y
+6.9%
6M
+32.9%
1M
+2.7%
1W
-3.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-29.52
PEG Ratio
N/A
P/B Ratio
2.12
P/S Ratio
16070.7
EV/Revenue
10676.5
EV/EBITDA
-2.06
Market Cap
$578.54M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1024630.0%
Gross Margin
100.0%
ROE
-86.98%
ROA
-29.83%
Growth
Revenue and earnings growth rates
Revenue Growth
-45.5%
Earnings Growth
N/A
Q/Q Revenue Growth
-45.45%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.21
Low debt
Current Ratio
5.28
Strong
Quick Ratio
5.0
Excellent
Cash/Share
$10.61
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-1021866.7%
Net Margin
-2345383.3%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.37x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-15
$N/A
2026-03-12
$-7.68
-244.1% surprise
2025-11-12
$-2.13
+19.4% surprise
2025-08-12
$-2.89
+19.4% surprise
Healthcare Sector Comparison
Comparing LYEL against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-86.98%
This Stock
vs
-86.0%
Sector Avg
+1.1%
(Above Avg)
Debt to Equity
0.21
This Stock
vs
3.51
Sector Avg
-94.1%
(Less Debt)
Revenue Growth
-45.5%
This Stock
vs
90.15%
Sector Avg
-150.5%
(Slower)
Current Ratio
5.28
This Stock
vs
3.67
Sector Avg
+44.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LYEL
Lyell Immunopharma, Inc.
|
BEARISH | $578.54M | - | -87.0% | -% | $24.8 | |
|
MDXG
MiMedx Group, Inc.
|
NEUTRAL | $582.38M | 12.25 | 21.6% | 11.6% | $3.92 | Compare |
|
HSTM
HealthStream, Inc.
|
BEARISH | $589.8M | 32.59 | 5.1% | 6.0% | $19.88 | Compare |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
BEARISH | $591.9M | 24.2 | -% | 8.1% | $3.63 | Compare |
|
BVS
Bioventus Inc.
|
BEARISH | $595.53M | 26.79 | 13.2% | 4.0% | $8.84 | Compare |
LYEL
Lyell Immunopharma, Inc.
BEARISH
Mkt Cap
$579M
P/E
-
ROE
-87.0%
Price
$24.8
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | ARCH VENTURE PARTNERS IX,L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 488,090 | $12,499,985 |
| 2026-03-06 | ARCH VENTURE FUND XIII, L..P | Beneficial Owner of more than 10% of a Class of Security | Purchase | 488,090 | $12,499,985 |
| 2026-02-11 | SEELY LYNN | Chief Executive Officer | Sale | 7,455 | $174,372 |
| 2026-02-11 | HILL STEPHEN J | Chief Operating Officer | Sale | 1,236 | $28,910 |
| 2026-02-11 | LEE GARY K | Officer | Sale | 1,671 | $39,085 |
| 2026-02-10 | SEELY LYNN | Chief Executive Officer | Sale | 438 | $10,127 |
| 2026-02-10 | HILL STEPHEN J | Chief Operating Officer | Sale | 109 | $2,520 |
| 2026-02-10 | LEE GARY K | Officer | Sale | 147 | $3,399 |
| 2026-02-10 | BULIS VERONICA SANCHEZ | Officer | Stock Award | 8,750 | - |
| 2026-02-10 | BULIS VERONICA SANCHEZ | Officer | Sale | 254 | $5,872 |
| 2026-02-09 | SEELY LYNN | Chief Executive Officer | Stock Award | 20,000 | - |
| 2026-02-09 | HILL STEPHEN J | Chief Operating Officer | Stock Award | 4,000 | - |
| 2026-02-09 | LEE GARY K | Officer | Stock Award | 4,000 | - |
| 2025-12-30 | BULIS VERONICA SANCHEZ | Officer | Sale | 2,072 | $74,181 |
| 2025-11-10 | SEELY LYNN | Chief Executive Officer | Sale | 412 | $6,637 |
ARCH VENTURE PARTNERS IX,L.L.C.
Beneficial Owner of more than 10% of a Class of Security
2026-03-06
488,090 shares
·
$12,499,985
ARCH VENTURE FUND XIII, L..P
Beneficial Owner of more than 10% of a Class of Security
2026-03-06
488,090 shares
·
$12,499,985
SEELY LYNN
Chief Executive Officer
2026-02-11
7,455 shares
·
$174,372
HILL STEPHEN J
Chief Operating Officer
2026-02-11
1,236 shares
·
$28,910
LEE GARY K
Officer
2026-02-11
1,671 shares
·
$39,085
SEELY LYNN
Chief Executive Officer
2026-02-10
438 shares
·
$10,127
HILL STEPHEN J
Chief Operating Officer
2026-02-10
109 shares
·
$2,520
LEE GARY K
Officer
2026-02-10
147 shares
·
$3,399
BULIS VERONICA SANCHEZ
Officer
2026-02-10
8,750 shares
BULIS VERONICA SANCHEZ
Officer
2026-02-10
254 shares
·
$5,872
SEELY LYNN
Chief Executive Officer
2026-02-09
20,000 shares
HILL STEPHEN J
Chief Operating Officer
2026-02-09
4,000 shares
LEE GARY K
Officer
2026-02-09
4,000 shares
BULIS VERONICA SANCHEZ
Officer
2025-12-30
2,072 shares
·
$74,181
SEELY LYNN
Chief Executive Officer
2025-11-10
412 shares
·
$6,637
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
5 analysts
Needham
2026-04-10
Buy
Citizens
2026-03-09
Market Outperform
HC Wainwright & Co.
2025-12-09
Neutral
Buy
HC Wainwright & Co.
2025-11-24
Neutral
Neutral
Past News Coverage
Recent headlines mentioning LYEL from our newsroom.
Newest → oldest
No matching news yet.